This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...

Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research in 2000 after his diagnosis. The foundation has funded over $3 billion in research aimed at developing treatments and ...

Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the ...

Leitrim Rose, Catherine Cullen, is hosting a pilates and wellness morning to fundraise ahead of the Dublin City Marathon this ...

Today's FDA approval of tavapadon makes it the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.

BUFFALO, N.Y. (WIVB) — Participants gathered in Williamsville Saturday for a celebration of movement, as the Parkinson’s ...

Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...

Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...

People living with Parkinson’s disease are hospitalized more often than other older adults, most often because of infections, falls, fractures, or other medical problems rather than Parkinson’s itself ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 ( Rexaceract) in People with Parkinson’s Disease Location : Hall D, 3 rd Floor, E-Poster Station 12 The International Parkinson ...

Michael J. Fox, who was 29 years old when he was diagnosed with Parkinson’s disease, founded the Michael J. Fox Foundation for Parkinson’s Research ...